Lupin has received the Establishment Investigation Report (EIR) from US Food and Drug Administration (USFDA) for the successful inspection of its Nagpur facility. The inspection was conducted in May 2018. The successful completion of the Nagpur facility inspection is a positive development as the company continues to meet and exceed international regulatory standards.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.